有机铬、炎症与胰岛素抵抗的相关性

目的研究有机铬、炎症、他汀类药物与胰岛素抵抗,及其与心、脑血管疾病方面的关系。方法筛选40岁以上的糖耐量异常(IGT)合并高血压患者60人、糖耐量异常合并高脂血症患者60人、糖耐量异常合并冠心病患者60人和非胰岛素依赖性糖尿病(T2DM)患者60人,进行分组,每一组随机分为3个小组:2个治疗组及对照组。治疗一组在原治疗方案基础上给予唐安一号(有机铬制剂)口服,治疗二组在原治疗方案基础上给予阿乐(阿托伐他汀钙片)口服,对照组维持原治疗方案,治疗4周。结果治疗一组空腹血糖(FBG)、空腹血清胰岛素(FINS)、甘油三酯(TG)、血清总胆固醇(TC)和血清低密度脂蛋白胆固醇(LDL-C)均低于对照组(P0.05),血清高密度脂蛋白胆固醇(HDL-C)高于对照组(P0.05)。治疗二组FINS、TG、TC、LDL-C和C-反应蛋白(CRP)低于对照组(P0.05),HDL-C高于对照组(P0.05)。4周治疗后,治疗一组、治疗二组HOMA-IR均低于对照组(P0.05)。结论有机铬及他汀类药物能增强胰岛素的生物学效应,调节糖脂代谢,改善胰岛素抵抗。

The relationship between chromium, inflammation and insulin resistance

Objective To study the organic chromium,inflammation,statins and insulin resistance,and their relationship with cardiovascular and cerebrovascular diseases.Method Patients aged over 40 with impaired glucose tolerance（IGT） were screened as follows： 60 patients with hypertension,60 patients with hyperlipidemia,60 with coronary artery diseases and 60 with non-insulin-dependent diabetes mellitus（T2DM）.Each group was randomly divided into three subgroups： two treatment groups and a control group.Based on the original treatment protocols,the Treatment group 1 in each group was given TANG One（organic Chromium agent） orally,Treatment group 2 was given atorvastatin calcium orally,and the control group was given the original treatment.The treatment periods were four weeks.Result The fasting blood glucose（FBG）,fasting serum insulin（FINS）,triglyceride（TG）,serum total cholesterol（TC） and serum low-density lipoprotein cholesterol（LDL-C） of Treatment groups 1 were lower than those of the control groups（P0.05）,with the serum high-density lipoprotein cholesterol（HDL-C） higher than those of control groups（P0.05）.The FINS,TG,TC,LDL-C and C-reactive protein（CRP） of Treatment groups 2 were less than those of the control groups（P0.05）,with the high density lipoprotein cholesterol higher than those of the control groups（P0.05）.After treatment for four weeks,both the HOMA-IR of Treatment groups 1 and 2 were lower than those of the control groups（P0.05）.Conclusion Organic chromium and statins can increase the biological effect of insulin to regulate glucose and lipid metabolism and improve insulin resistance.